Navigation Links
Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
Date:6/18/2009

ward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
2. Novavax Reports First Quarter 2009 Financial Results
3. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
4. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Early Retirement of $17 Million of Convertible Debt
6. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
9. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
11. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Berg, a biopharmaceutical company committed to uncovering health ... from its trials using its cancer drug BPM 31510 ... triple negative breast cancer, at the 51 st ... (ASCO), May 29 – June 2 in ... one of the first cancer drugs guided in development ...
(Date:6/1/2015)... , June 1, 2015  Albany Molecular ... today that it has signed a collaborative ... co-market their structure-based drug discovery services to ... of the three-year agreement, AMRI gains access ... and capabilities. HarkerBIO,s customers will be able ...
(Date:6/1/2015)... DUBLIN , May 29, 2015 /PRNewswire/ ... announced the addition of the "2015 ... Market" report to their offering. ... tables, and provides a comprehensive analysis of ... dynamics, size, growth, regulatory requirements, technological trends, ...
(Date:6/1/2015)... 29, 2015 Research and Markets ( ... "2015 Strategies in the UK Flow Cytometry ... This report presents a comprehensive analysis of the ... issues pertaining to the French flow cytometry practice, ... and technological trends with significant market impact during ...
Breaking Biology Technology:Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3Strategies in the UK Flow Cytometry Market 2015 2
... MONTVALE, N.J., May 13 Synvista Therapeutics,Inc. (Amex: ... a 160-patient Phase 2 study,of alagebrium in patients with ... A.G.E. [Advanced Glycation End Product],Breaker Alagebrium in Diastolic Heart ... the effect of six months,of oral treatment with 400mg ...
... Yields First Milestone, NEW YORK, May 13 ... pre-disease collection, processing and long-term,storage of adult stem cells ... been secured for a new stem cell collection center ... Smith, MD MBA, NeoStem,s Chairman and Chief Executive Officer,commented: ...
... May 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... Phase 2 study of subcutaneously,administered LHRH antagonist ... (BPH", has been accepted for publication in ...
Cached Biology Technology:Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 2AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 4AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 5AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 6
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... is measured to understand tree health, fluxes in carbon ... of the most essential and widely collected woody plant ... is awkward and time consuming. Scientists have developed a ... safely and accurately. Dendrometer bands are metal straps ...
... (IL-7) is an important immune messenger protein which ensures ... in our body for immune defence. Researchers from ETH ... function: it enhances the drainage function of lymphatic vessels, ... vessels into the body tissue and return it to ...
... an old dog new tricks." Now neuroscientists are beginning to ... neuroscientists have struggled to understand how the microcircuitry of the ... for the old. New findings published in the journal ... Los Angeles and the University of California, Irvine show how ...
Cached Biology News:New technique for measuring tree growth cuts down on research time 2New technique for measuring tree growth cuts down on research time 3New function for a well-known immune messenger molecule 2New function for a well-known immune messenger molecule 3Researchers discover how inhibitory neurons behave during critical periods of learning 2
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: D-hexose ... 2.7.1.1/1.1.1.49. One unit of HK ... D-glucose in 1 min at ... unit of G6P-DH will oxidize ...
Request Info...
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
Biology Products: